- In November 2024, Astellas Pharma Inc. announced that the FDA issued a Complete Response Letter (CRL) on November 15, 2024, regarding the supplemental New Drug Application (sNDA) for IZERVAY (avacincaptad pegol) for treating geographic atrophy (GA) due to age-related macular degeneration (AMD). This feedback provides Astellas with critical insights to refine its application and strengthen future regulatory submissions
- In October 2024, Annexon, Inc. announced that it will present new analyses of ANX007 from the completed Phase 2 ARCHER trial in geographic atrophy (GA) at the AAO 2024 annual meeting and the Eyecelerator conference on October 17-21, 2024, in Chicago. This will increase the company’s exposure in the ophthalmology field and potentially attract more interest in its GA therapies
- In September 2024, Boehringer Ingelheim and CDR-Life announced positive Phase I results for BI 771716, an investigational antibody fragment aimed at preserving vision in people with geographic atrophy (GA). This success could enhance the company's position in the GA market and drive further development of innovative treatments
- In July 2024, Ocugen, Inc. announced the completion of dosing in the third cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA), a novel gene therapy for geographic atrophy (GA). This progress positions the company for potential breakthroughs in GA treatment and strengthens its pipeline of innovative therapies
- In May 2024, Johnson & Johnson announced eight company-sponsored presentations at the ARVO 2024 Annual Meeting in Seattle, including two oral presentations on genetic testing for inherited retinal diseases (IRDs) and the use of deep-learning algorithms to measure precursors of geographic atrophy (GA). These presentations will enhance the company's thought leadership in ophthalmology and highlight its advancements in eye disease research
